Literature DB >> 16972907

A vision of cell death: Fas ligand and immune privilege 10 years later.

Thomas A Ferguson1, Thomas S Griffith.   

Abstract

Immune privilege is a term applied to organs that have a unique relationship with the immune response. These sites prohibit the spread of inflammation, since even minor episodes can threaten organ integrity and function. Once thought to be a passive process relying on physical barriers, immune privilege is now viewed as an active process, which uses multiple mechanisms to maintain organ function. The prototypic organ of immune privilege has been the eye, where the spread of inflammation can threaten vision. Nearly 10 years ago, we discussed the finding that Fas ligand (FasL) was constitutively expressed in the eye and played a major role in immune privilege by inducing apoptosis in inflammatory cells that enter the eye. In this review, we reexamine the original evidence for the role of FasL in immune privilege, update progress on some of the concepts, and discuss some of the issues that remain unresolved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972907     DOI: 10.1111/j.1600-065X.2006.00430.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  53 in total

1.  Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: the eye.

Authors:  Na Niu; Jie Zhang; Yingui Sun; Shuna Wang; Yonghong Sun; Christine Korteweg; Weiwei Gao; Jiang Gu
Journal:  Cell Mol Life Sci       Date:  2011-07       Impact factor: 9.261

2.  Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.

Authors:  Tuomo S Kokkonen; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2015-09-15       Impact factor: 2.479

Review 3.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

Review 4.  Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases.

Authors:  Madhu Ramaswamy; Min Deng; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

Review 5.  DNA damage-induced cell death: lessons from the central nervous system.

Authors:  Helena Lobo Borges; Rafael Linden; Jean Y J Wang
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

6.  Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis.

Authors:  Jian Shen; Ning-Xia Sun
Journal:  Tumour Biol       Date:  2013-07-31

Review 7.  Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.

Authors:  Chad Tang; Micha Drukker
Journal:  Semin Immunopathol       Date:  2011-04-11       Impact factor: 9.623

Review 8.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

9.  Effects of intravitreally injected Fc fragment on rat eyes.

Authors:  Tatjana Taubitz; Laura-Pia Steinbrenner; Alexander V Tschulakow; Antje Biesemeier; Sylvie Julien-Schraermeyer; Ulrich Schraermeyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-17       Impact factor: 3.117

10.  Alterations in myocardial gene expression associated with experimental Trypanosoma cruzi infection.

Authors:  Shankar Mukherjee; Fnu Nagajyothi; Aparna Mukhopadhyay; Fabiana S Machado; Thomas J Belbin; Antonio Campos de Carvalho; Fangxia Guan; Chris Albanese; Linda A Jelicks; Michael P Lisanti; Joao S Silva; David C Spray; Louis M Weiss; Herbert B Tanowitz
Journal:  Genomics       Date:  2008-03-17       Impact factor: 5.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.